Emergent BioSolutions Inc. (EBS)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Richard S. Lindahl M.B.A. | Executive VP, CFO & Treasurer | 1.02M | -- | 1964 |
| Ms. Jennifer L. Fox | Executive VP of External Affairs, General Counsel & Corporate Secretary | 975.84k | -- | 1973 |
| Ms. Coleen Glessner | Executive Vice President of Global Quality and Ethics & Compliance | 959.37k | -- | 1971 |
| Mr. Paul A. Williams | Senior Vice President of Products Business | 846.97k | -- | 1967 |
| Mr. Joseph C. Papa Jr. | CEO, President & Director | -- | -- | 1956 |
| Michelle Pepin | Senior VP & Chief Human Resource Officer | -- | -- | -- |
| Ms. Stephanie Duatschek | Senior VP, Chief Strategy & Transformation Officer | -- | -- | -- |
| Dr. Kelly Lyn Warfield | Senior VP of Science & Development | -- | -- | -- |
| William Hartzel | Senior Vice President of Manufacturing & Bioservices | -- | -- | -- |
Emergent BioSolutions Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Full Time Employees:
- 1,600
Description
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Corporate Governance
Recent Events
- Apr 11, 2024DEF 14A: Proxy StatementsSee Full Filing
- Mar 08, 202410-K: Periodic Financial ReportsSee Full Filing
- Mar 06, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Feb 21, 20248-K: Corporate Changes & Voting MattersSee Full Filing
- Jan 23, 2024SC 13G/A: Tender Offer/Acquisition ReportsSee Full Filing